Loading
NASDAQHealthcareBiotechnology
Latest quote
$0.4994
+$0.0107 · +2.19%
Citius Pharmaceuticals, Inc. operates as a specialized pharmaceutical firm concentrating on the development and market introduction of critical care products. Its efforts are particularly directed towards anti-infective treatments supporting cancer care, various prescription medications, and pioneering mesenchymal stem cell therapies. The company is actively advancing five unique products within its pipeline: Mino-Lok: An antibiotic lock solution designed to combat catheter-related bloodstream infections by salvaging the infected central venous catheter. Mino-Wrap: A novel liquifying gel-based wrap aimed at minimizing infections associated with tissue expanders following breast reconstructive procedures. Halo-Lido: A topical formulation that blends a corticosteroid with lidocaine, intended to deliver both anti-inflammatory and numbing relief to individuals suffering from hemorrhoids. NoveCite: A mesenchymal stem cell therapy currently under development for treating acute respiratory distress syndrome (ARDS). I/ONTAK: An engineered fusion protein, combining IL-2 and diphtheria toxin, purposed for the treatment of patients experiencing persistent or recurrent cutaneous T-cell lymphoma. Citius Pharmaceuticals, Inc. was founded in 2007 and is headquartered in Cranford, New Jersey.
Latest quote
$0.4994
+$0.0107 · +2.19%
After-hours
$0.49
−$0.0094 · -1.88%
Oct 9, 7:59 PM ET
Regular session · ET · Market data may be delayed.
Citius Pharmaceuticals, Inc. operates as a specialized pharmaceutical firm concentrating on the development and market introduction of critical care products. Its efforts are particularly directed towards anti-infective treatments supporting cancer care, various prescription medications, and pioneering mesenchymal stem cell therapies. The company is actively advancing five unique products within its pipeline: Mino-Lok: An antibiotic lock solution designed to combat catheter-related bloodstream infections by salvaging the infected central venous catheter. Mino-Wrap: A novel liquifying gel-based wrap aimed at minimizing infections associated with tissue expanders following breast reconstructive procedures. Halo-Lido: A topical formulation that blends a corticosteroid with lidocaine, intended to deliver both anti-inflammatory and numbing relief to individuals suffering from hemorrhoids. NoveCite: A mesenchymal stem cell therapy currently under development for treating acute respiratory distress syndrome (ARDS). I/ONTAK: An engineered fusion protein, combining IL-2 and diphtheria toxin, purposed for the treatment of patients experiencing persistent or recurrent cutaneous T-cell lymphoma. Citius Pharmaceuticals, Inc. was founded in 2007 and is headquartered in Cranford, New Jersey.
Day range
Current $0.4994
52-week range
Current $0.4994
Regular session · ET · Market data may be delayed.
GoAI Score
Sell
Valuation
61
Undervalued
Sentiment
55
Mixed
Risk
71
High Risk
Momentum
23
Weakening
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
Citius Pharmaceuticals, Inc. operates as a specialized pharmaceutical firm concentrating on the development and market introduction of critical care products. Its efforts are particularly directed towards anti-infective treatments supporting cancer care, various prescription medications, and pioneering mesenchymal stem cell therapies. The company is actively advancing five unique products within its pipeline: Mino-Lok: An antibiotic lock solution designed to combat catheter-related bloodstream infections by salvaging the infected central venous catheter. Mino-Wrap: A novel liquifying gel-based wrap aimed at minimizing infections associated with tissue expanders following breast reconstructive procedures. Halo-Lido: A topical formulation that blends a corticosteroid with lidocaine, intended to deliver both anti-inflammatory and numbing relief to individuals suffering from hemorrhoids. NoveCite: A mesenchymal stem cell therapy currently under development for treating acute respiratory distress syndrome (ARDS). I/ONTAK: An engineered fusion protein, combining IL-2 and diphtheria toxin, purposed for the treatment of patients experiencing persistent or recurrent cutaneous T-cell lymphoma. Citius Pharmaceuticals, Inc. was founded in 2007 and is headquartered in Cranford, New Jersey.
Day range
Current $0.4994
52-week range
Current $0.4994
Operating income
Net income
| Metric (USD) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Cost of goods sold | 214.25K USD | 209.61K USD | — | — | 164.87K USD |
| Gross profit | −214.25K USD | −209.61K USD | — | — | −164.87K USD |
| Research and development | 9.16M USD | 11.91M USD | 14.82M USD | 17.66M USD | 12.24M USD |
| Selling, general, and administrative | 18.53M USD | 18.25M USD | 21.91M USD | 15.66M USD | 11.13M USD |
| Operating expenses | 38.31M USD | 42M USD | 36.73M USD | 33.32M USD | 23.37M USD |
| Interest income | 110.08K USD | 758K USD | 1.18M USD | 251.4K USD | 261.82K USD |
| Interest expense | 267.78K USD | — | — | — | 10.84K USD |
| Depreciation and amortization | 214.25K USD | 209.61K USD | 194.32K USD | 179.68K USD | 164.87K USD |
| Operating income | −38.53M USD | −42M USD | −36.73M USD | −33.32M USD | −23.53M USD |
| Net income | −37.43M USD | −39.14M USD | −32.54M USD | −33.64M USD | −23.05M USD |
Company facts updated Oct 10, 2026.
Recent quarterly results
Recent quarterly results
Third-party consensus; not a GoAI recommendation.
| Action | Effective date | Details | Record date | Payment date |
|---|---|---|---|---|
Stock split | Jun 9, 2017 | 1:15 | — | — |
Effective Jun 9, 2017
1:15
Funds reporting this stock among their holdings, ordered by reported position size.
AI-generated and delayed market data for informational and educational purposes only. Not investment advice.
